Pioneering Novel ADC Payload Mechanisms in Oncology
Hexagon Bio is redefining the potential of antibody-drug conjugates (ADCs). By discovering and developing novel ADC payload mechanisms, beyond topoisomerase and tubulin inhibitors, Hexagon Bio is bypassing traditional resistance pathways and unlocking new frontiers in targeted cancer therapy.
Current ADC payloads are limited by toxicity and acquired resistance. We are tapping into new chemical space to discover potent, novel payloads with unique mechanisms of action. This allows us to target solid tumors and expand the reach of ADCs beyond current limitations.
Recent Milestones
Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC